ACB:CA:CDX-Aurora Cannabis Inc. (CAD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic | TSX Venture Exchange

Last Closing

USD 8.94

Change

0.00 (0.00)%

Market Cap

USD 0.76B

Volume

0.76M

Analyst Target

USD 16.10
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Aurora Cannabis Inc is a medical marijuana company. The Company is engaged in producing and distributing medical marijuana pursuant to the Marijuana for Medical Purposes Regulations.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-16 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
RX:CA Biosyent Inc.

+0.04 (+0.36%)

USD 0.13B
SBBC:CA Simply Better Brands Corp

+0.01 (+0.88%)

USD 0.10B
LOVE:CA Cannara Biotech Inc

N/A

USD 0.10B
HASH:CA Simply Solventless Concentrate..

-0.03 (-4.17%)

USD 0.08B
ZYUS:CA ZYUS Life Sciences Corporation

N/A

USD 0.06B
LSL:CA LSL Pharma Group Inc.

-0.02 (-5.48%)

USD 0.04B
DB:CA Decibel Cannabis Company Inc

-0.01 (-7.14%)

USD 0.04B
VM:CA Voyageur Pharmaceuticals Ltd

+0.01 (+3.03%)

USD 0.03B
ROMJ:CA Rubicon Organics Inc

-0.04 (-9.52%)

USD 0.02B
PCLO:CA Pharmacielo Ltd

N/A

USD 0.01B

ETFs Containing ACB:CA

CNDA Concord Acquisition Corp .. 0.00 % 0.70 %

N/A

USD 0.10B
AUGA:LSE UBS (Irl) ETF plc - MSCI .. 0.00 % 0.00 %

-30.00 (0%)

N/A
AUAD:LSE UBS (Irl) ETF plc - MSCI .. 0.00 % 0.00 %

-18.50 (0%)

N/A
HMXJ:LSE HSBC ETFs Public Limited .. 0.00 % 0.00 %

-5.50 (0%)

N/A
IAUS:LSE iShares MSCI Australia UC.. 0.00 % 0.00 %

-0.66 (0%)

N/A
DX2S:F 0.00 % 0.00 %

N/A

N/A
DXS6:F 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange (TSX Venture Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 46.32% 90% A- 99% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 46.32% 90% A- 99% N/A
Trailing 12 Months  
Capital Gain 71.92% 90% A- 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 71.92% 90% A- 94% A
Trailing 5 Years  
Capital Gain -96.58% 29% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -96.58% 29% F 1% F
Average Annual (5 Year Horizon)  
Capital Gain 363.04% 100% F 99% N/A
Dividend Return 363.04% 100% F 99% N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 2,390.21% 5% F 1% F
Risk Adjusted Return 15.19% 82% B 29% F
Market Capitalization 0.76B 61% D- 54% F

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector